Scholarlink

<p>The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), we analyzed RNA-sequencing in biopsies from men treated prospectively on an enzalutamide clinical trial. We focused on those with ENR (progression within 3 months) vs. long-term response (progression after 24 months). We identified an ENR program linked to proliferation, epithelial-to-mesenchymal transition, and stemness. High expression of this program in additional datasets was independently linked to poor tumor control with AR targeting but favorable tumor control with docetaxel, another standard treatment. CDK2 was implicated in the ENR program. CDK2 suppression reduced the ENR program and viability of ENR program-high prostate cancer models. The ENR gene program is predictive of non-response to AR targeting. Patients whose tumors harbor this program may be good candidates for docetaxel or CDK2 inhibitor clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Anbarasu Kumaraswamy,
  • Ya-Mei Hu,
  • Joel A. Yates,
  • Chao Zhang,
  • Eva Rodansky,
  • Dhruv Khokhani,
  • Diana Flores,
  • Zhi Duan,
  • Yi Zhang,
  • Shaadi Tabatabaei,
  • Rachel Slottke,
  • Shangyuan Ye,
  • Primo Lara,
  • Adam Foye,
  • Charles J. Ryan,
  • David A. Quigley,
  • Jiaoti Huang,
  • Rahul Aggarwal,
  • Robert E. Reiter,
  • Max S. Wicha,
  • Tomasz M. Beer,
  • Matthew Rettig,
  • Martin Gleave,
  • Christopher P. Evans,
  • Owen N. Witte,
  • Joshua M. Stuart,
  • George V. Thomas,
  • Felix Y. Feng,
  • Eric J. Small,
  • Zheng Xia,
  • Joshi J. Alumkal

摘要

The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), we analyzed RNA-sequencing in biopsies from men treated prospectively on an enzalutamide clinical trial. We focused on those with ENR (progression within 3 months) vs. long-term response (progression after 24 months). We identified an ENR program linked to proliferation, epithelial-to-mesenchymal transition, and stemness. High expression of this program in additional datasets was independently linked to poor tumor control with AR targeting but favorable tumor control with docetaxel, another standard treatment. CDK2 was implicated in the ENR program. CDK2 suppression reduced the ENR program and viability of ENR program-high prostate cancer models. The ENR gene program is predictive of non-response to AR targeting. Patients whose tumors harbor this program may be good candidates for docetaxel or CDK2 inhibitor clinical trials.